DexCom, Inc. (NASDAQ:DXCM) Short Interest Update

DexCom, Inc. (NASDAQ:DXCM) saw a significant decline in short interest in December. As of December 31st, there was short interest totalling 8,800,000 shares, a decline of 5.7% from the December 15th total of 9,330,000 shares. Based on an average daily volume of 3,910,000 shares, the days-to-cover ratio is currently 2.3 days.

Analyst Upgrades and Downgrades

DXCM has been the topic of a number of recent research reports. Baird R W upgraded shares of DexCom from a “hold” rating to a “strong-buy” rating in a report on Thursday. Oppenheimer cut their price target on DexCom from $115.00 to $105.00 and set an “outperform” rating on the stock in a research note on Friday, October 25th. Canaccord Genuity Group lifted their price objective on DexCom from $89.00 to $99.00 and gave the company a “buy” rating in a research note on Monday, December 9th. Citigroup increased their target price on DexCom from $85.00 to $91.00 and gave the stock a “buy” rating in a research note on Wednesday, December 11th. Finally, Royal Bank of Canada lowered their price target on DexCom from $120.00 to $115.00 and set an “outperform” rating for the company in a research report on Friday, October 25th. Five equities research analysts have rated the stock with a hold rating, twelve have given a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $99.29.

DexCom Stock Down 0.5 %

DXCM stock opened at $84.38 on Monday. The company has a market cap of $32.96 billion, a price-to-earnings ratio of 50.53, a P/E/G ratio of 2.00 and a beta of 1.12. The company has a debt-to-equity ratio of 1.23, a quick ratio of 2.12 and a current ratio of 2.46. The business’s 50-day moving average is $78.17 and its two-hundred day moving average is $77.75. DexCom has a fifty-two week low of $62.34 and a fifty-two week high of $142.00.

Insider Activity at DexCom

In other news, EVP Sadie Stern sold 4,259 shares of the business’s stock in a transaction on Wednesday, November 20th. The shares were sold at an average price of $74.73, for a total transaction of $318,275.07. Following the sale, the executive vice president now owns 71,192 shares in the company, valued at approximately $5,320,178.16. The trade was a 5.64 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. 0.30% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On DexCom

Several institutional investors have recently made changes to their positions in DXCM. Versant Capital Management Inc purchased a new stake in DexCom during the fourth quarter valued at approximately $25,000. Riverview Trust Co grew its position in shares of DexCom by 100.4% during the 3rd quarter. Riverview Trust Co now owns 463 shares of the medical device company’s stock valued at $31,000 after acquiring an additional 232 shares during the period. RPg Family Wealth Advisory LLC purchased a new stake in shares of DexCom in the 3rd quarter worth $57,000. Covestor Ltd raised its holdings in DexCom by 53.7% in the 3rd quarter. Covestor Ltd now owns 959 shares of the medical device company’s stock worth $64,000 after purchasing an additional 335 shares during the period. Finally, MassMutual Private Wealth & Trust FSB lifted its position in DexCom by 46.7% during the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 833 shares of the medical device company’s stock valued at $65,000 after purchasing an additional 265 shares in the last quarter. Institutional investors own 97.75% of the company’s stock.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.